Kyle Hoffmann

Not every company has the scale or resources of a Novartis or Lantheus. Smaller and emerging radioligand therapy developers face unique supply chain challenges, from isotope production and transport to distribution and patient delivery.

Inefficiencies, high costs, and limited access to optimized logistics networks can slow commercialization and reduce first-pass yield.

• Scaling Supply Chains: Identifying bottlenecks from preclinical production to clinical and commercial distribution
• Transport and Delivery Optimization: Exploring route planning, aircraft selection, and scheduling strategies to reduce waste and costs
• Leveraging Industry Resources: Discussing practical solutions for smaller companies to access shared logistics, third-party services, and best practices

–

Outcome – A facilitated supply chain consultation session where participants:

• Present key operational and logistical challenges
• Collaborate with experts and peers to explore practical solutions for transport, distribution, and cost efficiency
• Receive tailored guidance on scalable strategies to improve delivery reliability and patient access
• Develop actionable next steps to strengthen supply chain operations